✦ LIBER ✦

Development of humanized antibodies as cancer therapeutics

✍ Scribed by Zhengxing Qu; Gary L. Griffiths; William A. Wegener; Chien-Hsing Chang; Serengulam V. Govindan; Ivan D. Horak; Hans J. Hansen; David M. Goldenberg

Book ID: 116986557
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 459 KB
Volume: 36
Category: Article
ISSN: 1046-2023
DOI: 10.1016/j.ymeth.2005.01.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antibody targeted drugs as cancer therap

Antibody targeted drugs as cancer therapeutics

✍ Schrama, David; Reisfeld, Ralph A.; Becker, Jürgen C. 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 633 KB

Development trends for monoclonal antibo

Development trends for monoclonal antibody cancer therapeutics

✍ Reichert, Janice M.; Valge-Archer, Viia E. 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 265 KB

Development trends for human monoclonal

Development trends for human monoclonal antibody therapeutics

✍ Nelson, Aaron L.; Dhimolea, Eugen; Reichert, Janice M. 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 334 KB

Antibody-DM1 conjugates as cancer therap

Antibody-DM1 conjugates as cancer therapeutics

✍ Manu Lopus 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 529 KB

Monoclonal antibodies as therapeutic age

Monoclonal antibodies as therapeutic agents for cancer

✍ Marion Harris 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 241 KB

Human PLG Antibodies as a HNSCC Therapeu

Human PLG Antibodies as a HNSCC Therapeutic Benefit

✍ Isaac Dingle; James Byrd; Brian Hoel; M. Boyd Gillespie; Natalie Sutkowski 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 43 KB